Study on Safety and Effectiveness of Citrate Anticoagulation in Continuous Kidney Therapy for Adults with Liver Failure and Severe Shock

What this Trial Is About

Researchers are studying patients with acute kidney injury AKI who require continuous renal replacement therapy CRRT, focusing on those with liver failure or significant liver dysfunction and severe shock. The goal is to understand how different causes of liver failure affect the safety and effectiveness of using citrate as an anticoagulant during CRRT. This retrospective cohort study aims to clarify the risks of citrate-related complications and compare treatment outcomes in this vulnerable population. Citrate anticoagulation works by binding calcium to prevent blood clotting in the CRRT circuit, and is usually processed by the liver. However, impaired liver function can cause citrate to build up, potentially leading to metabolic problems. This study will assess whether the cause of liver failure influences the frequency of such complications. It also compares kidney recovery, filter lifespan, and patient survival between patients with liver failure or dysfunction and those with severe shock. Participants medical records will be reviewed during their ICU admission to evaluate citrate-related safety outcomes and treatment effectiveness. Researchers will analyze data on metabolic status, filter performance, and survival rates. The study focuses on the time patients spend receiving CRRT in the ICU to measure these outcomes and gather insights on managing anticoagulation in this high-risk group.

Efficacy and Safety of Citrate Anticoagulation in CRRT for Patients With Liver Failure/DysfuncTION, the CAUTION Trial! A Retrospective Study on Etiology of Liver Failure and Their Complications